Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10p -4.17% 2.30p 272,526 15:58:39
Bid Price Offer Price High Price Low Price Open Price
2.10p 2.50p 2.40p 2.30p 2.40p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.19 8.2

Hemogenyx Pharmaceuticals (HEMO) Latest News

More Hemogenyx Pharmaceuticals News
Hemogenyx Pharmaceuticals Takeover Rumours

Hemogenyx Pharmaceuticals (HEMO) Share Charts

1 Year Hemogenyx Pharmaceuticals Chart

1 Year Hemogenyx Pharmaceuticals Chart

1 Month Hemogenyx Pharmaceuticals Chart

1 Month Hemogenyx Pharmaceuticals Chart

Intraday Hemogenyx Pharmaceuticals Chart

Intraday Hemogenyx Pharmaceuticals Chart

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
18/5/201904:56HEMOGENYX 2018/19 Moderated1,577
06/11/201807:57Hemogenyx Blockbuster IP licencing to Big Pharma43
28/10/201820:32Davevt2
28/9/201811:36Hemogenyx (HEMO) One to Watch -
10/8/201810:16HEMO824

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hemogenyx Pharmaceuticals trades in real-time

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

DateSubject
19/5/2019
09:20
Hemogenyx Pharmaceuticals Daily Update: Hemogenyx Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 2.40p.
Hemogenyx Pharmaceuticals Plc has a 4 week average price of 2.25p and a 12 week average price of 2.13p.
The 1 year high share price is 4.95p while the 1 year low share price is currently 1.95p.
There are currently 356,042,854 shares in issue and the average daily traded volume is 315,432 shares. The market capitalisation of Hemogenyx Pharmaceuticals Plc is £8,188,985.64.
29/4/2019
15:34
badger60: Interesting....the bid has remained firm around the 2.2p mark for the last 3-4weeks...... except for a short period where shares were sold/bought at 2.14p. I estimate that 6mio + have changed hands over this period. Obviously there has been a sizeable seller(s), but I reckon the buyers could be......An investor who looking to accumulate a sizable position..........buying shares to cover Sir Marc Feldmann's renumeration.........and/or the company broker supporting the share price, hopefully with the backing of client interest.
27/3/2019
09:59
davevt: Oh badger, hemo paid align for their report in shares, they are nothing more than marketing tools used by companies like this to try and ramp their share price. That's where the lack of integrity lies, in the companies that pay them to make rampy reports. They don't 'recommend' anyone unless you pay them to. If you think they have dumped their 'free' shares they are probably privy to some forthcoming bad news with hemo.
30/1/2019
07:23
tullynessle: https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Presentation-at-Canc/79143221 Hemogenyx Pharmaceuticals PLC Presentation at Cancer Immunotherapy Conference 30/01/2019 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit' conference Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that its CEO Dr Vladislav Sandler will present at the conference 'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit'. The conference is taking place in Whistler, Canada from 10 to 14 March 2019 and is organized within the Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/Egxj3V). Dr Sandler's presentation is entitled 'A Novel Anti-FLT3-CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia and Conditioning of Patients for Hematopoietic Stem Cell Transplantation'. The presentation will highlight the fact that, despite numerous advances in understanding the biology and pathogenesis of acute myeloid leukemia (AML), treatment remains unsatisfactory and that relapsed or refractory AML is nearly universally fatal. The presentation will describe the state of development of the Company's CDX antibodies and their potential benefit for the treatment of AML and conditioning of patients for hematopoietic stem cell (HSC) transplantation. Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/epxTuf) is a nonprofit organization with a 47-year history of convening open, peer-reviewed conferences that connect the scientific community and accelerate life science discovery. Its Scientific Advisory Board is comprised of eminent biomedical scientists whose expertise derives from academia, industry, and the government (https://goo.gl/GtwUjT).
29/1/2019
01:14
badger60: It'll be interesting to see what impact the Northland report has on the share price All well and good if it attracts fresh investors, as technically there may be some weakly held stock that needs placing into firm hands at the current 3.5pps which was the issue price 16 months ago. Once this has happened, given that the company continues to progress as expected, my guess is that the share price will be in double figures well before the year is out...... giving a market cap of 36mio+, or pushing on further towards Align's forecasted 70mio market cap.
10/1/2019
09:53
tullynessle: New Subject It might be interesting to identify the "one or more qualified investors (the "Investors")", mentioned in the RNS. I suppose all will become clear if conversion rights are exercised? Extract: "According to the terms of the agreement, Orgenesis and/or one or more qualified investors (the "Investors") will advance to Immugenyx a convertible loan in an amount of not less than US$1,000,000 (the "Convertible Loan"). As part of the Agreement, the Investors shall have the right to convert the outstanding Convertible Loan amount into either: (i) shares of Immugenyx at a price per share based on a pre-money valuation of US$8,000,000; or (ii) shares of Orgenesis' common stock at a price per share equal to the weighted average trading price of Orgenesis' common stock for the three trading days preceding conversion. Orgenesis and/or the Investors shall have the option, exercisable at any time up to the third anniversary of the closing of the transaction, to invest additional funds in an amount of up to US$1,000,000 and not less than US$500,000 in Immugenyx." https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Collaboration-Licen/78495925 HEMOGENYX _ RNS 19/10/2018 Hemogenyx Pharmaceuticals PLC Collaboration, License and Investment by Orgenesis Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its wholly owned subsidiary Immugenyx, LLC ("Immugenyx") has entered into a collaboration agreement with Orgenesis, Inc ("Orgenesis"). Orgenesis (NASDAQ: ORGS) is a vertically-integrated biopharmaceutical company with expertise and experience in cell therapy development and manufacturing. News Release continues......
07/1/2019
10:42
asat91: Well yes at the moment only the subsidiaries have a valuation. The valuations aren't plucked out of thin air, they are based on money invested in the companies. So that's why the 2 subsidiaries have a specific current value of $8mill and $12mill. CDX antibodies is a potential therapy product that has potential revenues in the future after it has gone through clinical trials, but it has no current value. I'm not saying that it is useless or that the product won't be successful! I'm simply saying that you cannot put a specific value on CDX antibodies product at the moment. Since the valuation of the 2 subsidiaries is double the current market cap of the parent company, the HEMO share price should be about 5p at the moment + maybe a little bit for potential CDX value which will increase with every deal/clinical trial the product goes through.
23/10/2018
09:34
davevt: Badger, how many companies like that throw out leaked tweets to pump share prices, file 'provisional' patent applications which are not patent applications at all in a way to pump share prices, how many companies after getting a client then tell their investors they sucked in on the pump that they are now slicing and dicing any revenues between shell companies. It doesn't matter the credentials, it doesn't matter how good the product is, what matters to share holders is the bottom line. Currently you have no cash, just share options, which aren't even directly held by the main company now, you have a product sans patent, and you have two big deals according to you which actually dropped the share price and only a handful of people were interested. Go and argue with the market, I'm just the messenger.
19/9/2018
21:38
tullynessle: I don't believe it was the tweet. Hemogenyx were speaking recently at the "From Laboratory to Clinic: Accelerating Experimental Medicine Approaches" conference (Sept 4 thru Sept 7), at Trinity College, Oxford. Is it possible that their presentation updated/influenced the conference audience? More details in the posts dated 3 Sept and copied below. Tullynessle 3 Sep '18 - 20:31 - 494 of 539 Edit 0 0 0 Of the thirty one (31) confirmed speakers at the "From Laboratory to Clinic: Accelerating Experimental Medicine Approaches" conference (Sept 4 thru Sept 7), - 28 speakers represent international Universities & Medical/Research Institutes - 1 speaker represents SomaLogic [https://somalogic.com/] - 1 speaker represents Genentech a Member of the Roche Group [https://www.gene.com/] - 1 speaker represents HemoGenyx [https://www.hemogenyx.com/home/default.aspx] I suspect that all is well earned recognition for Dr Vladislav Sandler Ph.D. and the Hemogenyx team. Extract: CONFIRMED SPEAKERS *Bob Anderson (Walter and Eliza Hall Institute, AU) *Pamela Bjorkman (Caltech, USA) *Helen Blau (Stanford University, UA) *Jeffrey Bluestone (UCSF, USA) *Christopher Buckley (University of Oxford, UK) *Dennis Burton (Scripps Research Institute, USA) *Calliope Dendrou (University of Oxford, UK) *Peter Donnelly (University of Oxford, UK) *Kevan Herold (Yale University, USA) *Richard Hodes (NIH National Institute on Aging, USA) *Nebojsa Janjic (Somalogic, USA) *Yvonne Jones (University of Oxford, UK) *Luke Jostins-Dean (University of Oxford, UK) *Carl June (University of Pennsylvania, USA) (TBC) *Michael Karin (UCSD, USA) *Purvesh Khatri (Stanford University, USA) *Simon Leedham (University of Oxford) *Francis Lund (University of Alabama at Birmingham, USA) *Ira Mellman (Genentech, USA) *Michel Nussenzweig (Rockefeller University, USA) *Jeffrey Ravetch (Rockefeller University, USA) *Soumya Raychaudhuri (Harvard Medical School, USA) *Alexander Rudensky (Memorial Sloan Kettering Cancer Centre, USA) *Vladislav Sandler (HemoGenyx) *Owen Sansom (University of Glasgow, UK) *Lawrence Steinmam (Stanford University, USA) *Gitta Stockinger (Crick, UK) *Sarah Teichmann (Wellcome Sanger Institute, UK) *Craig Thompson (Memorial Sloan Kettering Cancer Centre, USA) (TBC) *Carola Vinuesa (ANU College of Health & Medicine, AU) *Georg Wick (Medizinische Universität Innsbruck, AT) https://www.kennedy.ox.ac.uk/more-events/2018-from-lab-to-clinic KENNEDY INSTITUTE OF RHEUMATOLOGY From Laboratory to Clinic: Accelerating Experimental Medicine Approaches Tuesday, 04 September 2018 to Friday, 07 September 2018 Trinity College, Oxford From Laboratory to Clinic is an annual translational research conference established in 1984. It is organised by an international committee led by past and present Directors of the Kennedy Institute, Profs Sir Marc Feldmann, Sir Ravinder Maini and Fiona Powrie. The meeting brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. TOPICS * Artificial Intelligence * Immune Regulation * Genetics/Genomics * Inflammation, Repair and Cancer * B cells: Basic to Clinical * Experimental Medicine Continued..... Tullynessle3 Sep '18 - 20:33 - 495 of 539 Edit 0 0 0 Re Post 494 https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Hemogenyx-to-present/78177372 Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference 03/09/2018 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'From Laboratory to Clinic' Translational Research Conference in Oxford Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference 'From Laboratory to Clinic: Accelerating Experimental Medicine Approaches' taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018. Continued.....
03/9/2018
20:33
tullynessle: Re Post 494 https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Hemogenyx-to-present/78177372 Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference 03/09/2018 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'From Laboratory to Clinic' Translational Research Conference in Oxford Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference 'From Laboratory to Clinic: Accelerating Experimental Medicine Approaches' taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018. Continued.....
27/6/2018
12:08
badger60: My friend, a significant HEMO shareholder, attended yesterday and sent me this last night.....My question on monetizing mice went down well the answer is that $375k already this year and $3 m in three years and $4m in five years. This will reduce cash burn to zero . Car-t and hemogenyx are totally separate for different cancers and one cannot be used to treat the same cancer as Hemo are targeting as the delivery systems are totally different. Hemo uses antibodies which are 100 smaller and more deliverable than a t cell. Sanofi Roche and Pfizer are the only companies that fit the market cap that is eluded to as being big enough for the tie up to get Hemogenyx list of antibodies to get FDA approval. The company will collaborate with Hemogenyx and pay the cost of obtaining approval so negating the need for massive rights issue. Hemogenyx royalties will be a lot less but say 10%. An example is AML which is expected to cost .5m dollars per course and 10m expected cases in the states gives $5m a patient may need multiple courses say only 2 that's 10m in the states and roughly same for europe so one antibody upwards of $20m and say they get 10% that's $2bn per antibody to Hemogenyx year after year. It's not difficult to see that in five years time the income could be the same as the current market cap. Then times that by the large number of antibodies and the sky's the limit! A cautionary note Hemogenyx was reversed into a fintech company and coo reckons half free float of 100m shares are in weak hands and are sellers at 5-6p so they get out flat from the original company once they are gone in estimated 1 year then they believe share price will be 9-10 p. All of this is subject to filing at the fda and i think it will be around 12p on that news!! I have a presentation pack which i can photo and send but it is no extra news than you already know.
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
LSE
HEMO
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190519 13:20:03